T2CMR Phantom
T2CMR Phantoms standardize cardiac T1 and T2 mapping, developed by experts.

Resonance Health operates as a MedTech company developing non-invasive medical imaging analysis.
resonancehealth.comCrawled Nov 13, 2026
T2CMR Phantoms standardize cardiac T1 and T2 mapping, developed by experts.
Medical imaging articles highlight the clinical value of Resonance Health’s solutions.
Resonance Health partners with biopharmaceutical companies and CROs for quality-assured clinical trials, supported by Australian government subsidies.
Resonance Health provides research tools for clinical studies, customizable by organ of interest.
Resonance Health’s products support clinicians and radiologists in diagnosing and managing patients across clinical settings.
Resonance Health’s medical imaging focuses on metabolic disease, liver-related disease, and iron overload disorders.
The page describes non-invasive methods to measure iron levels and assess liver iron storage.
MRI advancements enable tissue iron measurement for conditions like hereditary hemochromatosis and thalassemia.
Resonance Health shares medical imaging news, articles, and events on its news and resources page.
Resonance Health’s PoC study for liver fibrosis uses MRI biomarkers to achieve clinical outcomes.
Magnetic resonance imaging shifts toward quantitative analysis for disease insights.
Date: March 17-19, 2025Location: Milan, Italy
Date: May 07-10, 2025Location: Amsterdam, the Netherlands
T1CMR Phantoms are available for 1.5 T and 3 T scanners, designed by cardiologists, physicists, and engineers.
The Resonance team comprise a range of experts across medicine, business, law, and more, with decades of experience in technology commercialisation.
Resonance Health is a MedTech company headquartered in Australia, that specialises in the development of non-invasive medical imaging analysis.
Resonance Health is a MedTech company specialising in the commercialisation of non-invasive medical imaging analysis and clinical trial services.
Resonance Health ensures quality assurance for its medical device products, including regulatory-cleared and research-only devices.
Resonance Health’s R&D focuses on liver fibrosis, cardiac T2*, FerriScan improvements, and AI diagnostics.
Resonance Health offers advanced imaging solutions that enable doctors to enhance decision-making, tailor patient care, and achieve superior outcomes.
Professor Tim St Pierre discusses emerging directions in MRI technology. He highlights potential advancements that could reshape diagnostic imaging over the next five years. The conversation explores innovations likely to improve accuracy, speed, and accessibility in medical diagnostics.
Resonance Health develops MRI techniques to measure tissue iron levels more accurately. These advancements support diagnosis and monitoring of iron-overload disorders such as hereditary hemochromatosis and thalassemia. Improved imaging precision enables earlier intervention and better patient management.
Resonance Health investigates non-invasive techniques to assess liver iron levels, addressing the need for safer alternatives to invasive measurement methods. The liver serves as the main storage site for iron in the body, and current diagnostic approaches may pose risks or discomfort. The company examines potential approaches to improve iron overload detection without procedures like biopsies.
Resonance Health explains how the human body regulates iron absorption, transportation, utilization, and storage. Iron enters through the digestive system and undergoes a tightly controlled process to support physiological functions. The article highlights the risks of iron overload when this balance is disrupted.
Resonance Health develops MRI-based predictive models to quantify liver fibrosis and inflammation using proprietary analysis methods. The company’s proof-of-concept study compares results against liver biopsy as a reference standard, showing promising outcomes. A follow-up study will refine statistical power by including more balanced fibrosis gradings, supporting future regulatory validation.